This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AbbVie, Besins ask Third Circuit to revisit US FTC's AndroGel case

( November 16, 2020, 22:31 GMT | Official Statement) -- MLex Summary: AbbVie and Besins Healthcare have asked the US Court of Appeals for the Third Circuit to hold a rehearing en banc regarding reverse payment claims filed by the Federal Trade Commission. The Third Circuit ruled that the companies must face the claims concerning the testosterone treatment AndroGel in September. The drugmakers said that the decision conflicts with precedent and will chill First Amendment rights, undermine the attorney-client privilege, and subvert the Hatch-Waxman framework.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections